Found 6 articles
The acquisition is expected to bolster ACADIA’s clinical pipeline to include non-opioid pain therapies that have potential non-addictive properties and reduced side effects typically seen with current opioid treatments.
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the acquisition of CerSci Therapeutics, a clinical-stage biotechnology company with worldwide rights to a portfolio of novel compounds for neurological conditions, including non-opioid therapies for acute and chronic pain.
CerSci Therapeutics Awarded Phase I STTR Grant From the National Institute of Neurological Disorders and Stroke of the National Institutes of Health to Test Feasibility of a New Therapeutic Approach to Treat Migraine
CerSci Therapeutics, a non-opioid drug development firm based in Dallas, Texas has received notice from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) that it has been awarded a Phase I Small Business Technology Transfer (STTR) grant totaling over $220,000. These funds will support the preclinical development of novel, proprietary small-molecules for the treatment of migraine.
CerSci Therapeutics Awarded Phase II SBIR Grant From The National Institute On Drug Abuse Of The NIH
Non-Opioid Drug Development Firm, CerSci Therapeutics, Announces Appointment Of Pharma Leaders Pat Confalone And Perry Molinoff To The Board Of Directors